Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solriamfetol - Jazz Pharmaceuticals/SK Biopharmaceuticals

Next Previous
Drug Profile

Solriamfetol - Jazz Pharmaceuticals/SK Biopharmaceuticals

Alternative Names: ADX-N05; ARL-N05; JZP-110; SKL-N05; SUNOSI; Sunosi

Latest Information Update: 02 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SK Holdings
  • Developer Axsome Therapeutics; Jazz Pharmaceuticals plc; SK biopharmaceuticals
  • Class Antidepressants; Behavioural disorder therapies; Carbamates; Sleep disorder therapies; Small molecules
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Trace amine-associated receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Narcolepsy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypersomnia
  • Phase III Attention-deficit hyperactivity disorder; Binge-eating disorder; Circadian rhythm sleep disorders; Depressive disorders; Major depressive disorder

Most Recent Events

  • 24 Feb 2026 Phase-III clinical trials in Depressive disorders (PO)
  • 23 Feb 2026 Axsome Therapeutics plans a phase III trial for Major depressive disorders in the first quarter of 2026
  • 23 Feb 2026 Axsome Therapeutics plans a two phase III clinical trials for Attention-deficit hyperactivity disorder (In Adolescents, In children) in the first half of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top